Dashboard
Manage Tickers

ONC BeiGene, Ltd.

Nasdaq beigene.com


$ 374.21 $ 25.40 (7.28 %)    

Wednesday, 12-Nov-2025 13:48:22 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 620.37 $ -4.39 (-0.7 %)
DIA $ 483.30 $ 2.80 (0.58 %)
SPY $ 683.35 $ -1.44 (-0.21 %)
TLT $ 90.13 $ 0.18 (0.2 %)
GLD $ 387.09 $ 6.94 (1.83 %)
$ 343.65
$ 349.00
$ 373.50 x 54
$ 374.49 x 40
$ 349.00 - $ 374.15
$ 170.99 - $ 355.30
234,610
na
38.03B
$ 1.05
$ 554.74
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-27-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-26-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-02-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-27-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-02-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 02-28-2018 12-31-2017 10-K
33 11-13-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-22-2017 12-31-2016 10-K
37 11-10-2016 09-30-2016 10-Q
38 08-10-2016 06-30-2016 10-Q
39 05-12-2016 03-31-2016 10-Q
40 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Citigroup Maintains Buy on BeOne Medicines...
11/10/2025 21:31:06

Citigroup analyst Yigal Nochomovitz maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $399 ...

Core News & Articles
RBC Capital Maintains Outperform on BeOne ...
11/07/2025 18:17:32

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and raises the price target fro...

Core News & Articles
Citizens Maintains Market Outperform on Be...
11/07/2025 13:58:00

Citizens analyst Reni J. Benjamin maintains BeOne Medicines (NASDAQ:ONC) with a Market Outperform and raises the price targe...

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

Core News & Articles
BeOne Medicines Raises FY2025 Sales Guidan...
11/06/2025 11:02:22

BeOne Medicines (NASDAQ:ONC) raises FY2025 sales outlook from $5.000 billion-$5.300 billion to $5.100 billion-$5.300 billion.

Core News & Articles
BeiGene Q3 Adj. EPS $2.65 Beats $0.80 Esti...
11/06/2025 11:01:51

BeiGene (NASDAQ:ONC) reported quarterly earnings of $2.65 per share which beat the analyst consensus estimate of $0.80 by 231.2...

Core News & Articles
Morgan Stanley Maintains Overweight on BeO...
10/20/2025 15:25:30

Morgan Stanley analyst Sean Laaman maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from...

whats-going-on-with-summit-therapeutics-stock-on-monday
What's Going On With Summit Therapeutics S...
10/20/2025 14:05:00

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late...

Core News & Articles
Beone Medicines Announced The Presentation...
10/20/2025 10:10:02

Core News & Articles
The FDA Has Granted Breakthrough Therapy D...
10/13/2025 10:02:54

The decision by the FDA to grant sonrotoclax BTD and participation in Project Orbis was based on data from the BGB-11417-201 st...

Core News & Articles
Where BeOne Medicines Stands With Analysts
10/08/2025 18:00:49

Core News & Articles
JP Morgan Maintains Overweight on BeOne Me...
10/08/2025 17:33:30

JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $345...

Core News & Articles
Analyst Expectations For BeOne Medicines's...
09/18/2025 12:01:19

Core News & Articles
Barclays Initiates Coverage On BeOne Medic...
09/18/2025 11:18:09

Barclays analyst Peter Lawson initiates coverage on BeOne Medicines (NASDAQ:ONC) with a Overweight rating and announces Pric...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/10/2025 12:11:03

wayfair-united-therapeutics-and-ciena-are-among-the-top-10-large-cap-gainers-last-week-sep-1-sep5-are-the-others-in-your-portfolio-corrected
Wayfair, United Therapeutics, And Ciena Ar...
09/07/2025 14:30:00

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

air-lease-ionis-pharmaceuticals-arrowhead-pharmaceuticals-and-other-big-stocks-moving-higher-on-tuesday
Air Lease, Ionis Pharmaceuticals, Arrowhea...
09/02/2025 14:41:45

Core News & Articles
Market-Moving News for September 2nd
09/02/2025 11:23:26

ONC: 9% | BeOne Medicines shares are trading higher after the company last week announced topline results from a Phase 1/2 stud...

why-carisma-therapeutics-shares-are-trading-higher-by-133-here-are-20-stocks-moving-premarket
Why Carisma Therapeutics Shares Are Tradin...
09/02/2025 09:28:56

beone-medicines-stock-gains-momentum-with-early-stage-trial-success-for-pretreated-lymphoma-patients
BeOne Medicines Stock Gains Momentum With ...
08/29/2025 14:16:02

BeOne Medicines reported positive Phase 1/2 results for sonrotoclax in relapsed or refractory mantle cell lymphoma, with regula...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION